Roanoke, WV | Sept 2024
On September 19th, Winston Henderson, VP, General Counsel, Peter Howe, CFO, and Charlotte Leggett, Scientific Liaison, of Clear Scientific, Inc. attended the annual meeting of the WVACEP, the West Virginia Chapter of the American College of Emergency Physicians, in Roanoke, WV.
West Virginia has been heavily impacted by the overdose epidemic and is the U.S. state with the highest number of overdose deaths involving methamphetamine per capita (Center of Disease Control (CDC) 2021 - 2022).
The WV ACEP was a conference of 70+ Emergency Physicians who gathered to share best practices. There was strong consensus in the need for new therapeutics to treat meth and polysubstance overdose.
Patients presenting with methamphetamine and/or polysubstance intoxication can spend as much as one to three days in an ED bed. These patients strain Emergency Departments of their already limited resources. A therapy that could rapidly reverse methamphetamine or polysubstance intoxication would improve patient outcomes and turn-around times, alleviating these seemingly intractable resource challenges in the ED.
Clear Scientific is developing a novel therapeutic to treat methamphetamine, fentanyl, and polysubstance overdose. It is our hope that this work will help to mitigate some of the devastating effects of the polysubstance crisis in West Virginia.
About Clear Scientific
Clear Scientific, a clinical-stage biopharmaceutical company co-founded by George Whitesides of Harvard University, is pioneering a new paradigm for treatment of conditions and diseases that involve an excess of specific compounds in the body. This approach focuses on development of highly selective, small molecule sequestrants that bind, immediately inactivate, and rapidly clear excess compounds from the body.
For more information, visit https://www.clearsci.com.
Pictured left to right - Winston Henderson, VP, General Counsel, Charlotte Leggett, Scientific Liaison, and Peter Howe, CFO.
Comments